PD-L1 (SP142) Antibody Developed By Spring Bioscience To Be Studied As Cancer Immunotherapy

PD-L1 (SP142) Antibody Developed By Spring Bioscience To Be Studied As Cancer Immunotherapy

shutterstock_199033223A new PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody developed as a part of Roche/Genentech’s anti-PD-L1 (MPDL3280A) immunotherapy program has been released commercially by Spring Bioscience (Spring), a member of the Roche Group and known in the research industry for the development of highly specific antibodies used both in research and in the clinic.

It has become increasingly evident that measuring the amount of PD-L1 protein on the surface of both tumor cells and tumor infiltrating lymphocytes (TILs) is a major necessity, since PDL-1 is one of the immune checkpoints that are being exponentially targeted in the development of new immunotherapies against several types of cancers.

For example, nivolumab is a fully human IgG4 monoclonal antibody targeted to inhibit PD-1 that is currently being tested in metastatic renal cell carcinoma and advanced lung cancer.

Just recently, Immuno-Oncology News covered different clinical trial results presented at the American Society of Clinical Oncology (ASCO), the majority of which focused on anti-PD-L1 therapies.

Studies developed by Spring researchers showed that PD-L1 (SP142) antibody preformed significantly better than other commercially available PD-L1 antibodies, meeting the company’s high standards as a valuable tool for assessing PD-L1 expression in many different tumor types.

“As with all IHC antibodies developed by Spring, the SP142 antibody will deliver the high quality and accuracy that clinical researchers need to confidently assess PD-L1 status in tissue samples,” Michael Rivers, GM,¬†Spring Biosience said in a PR Newswire press release.

“The development of the PD-L1 (SP142) antibody was designed to be very sensitive and specific.¬†As researchers strive to understand the clinical relevance of PD-L1 expression, this clone may offer a superior ability to stain and analyze both tumor and immune cells,” Doug Ward, VP and Lifecycle Leader, Ventana Companion Diagnostics added in the same press release.

Leave a Comment

Your email address will not be published. Required fields are marked *